Introduction
============

Colorectal cancer (CRC) is one of the most common types of cancer in men and women, and the third leading cause of cancer-associated mortality in the United States ([@b1-ol-0-0-10742]). Age is the most significant risk factor ([@b2-ol-0-0-10742]), and as more individuals shift to a western diet and lifestyle, the incidence of CRC increases ([@b3-ol-0-0-10742]). Up to 5% of all CRC cases are caused by hereditary syndromes, which include polyposis and nonpolyposis CRCs ([@b4-ol-0-0-10742],[@b5-ol-0-0-10742]). Endoscopic polypectomy is an effective method to reduce the incidence and mortality of early-stage CRC ([@b6-ol-0-0-10742]), but the majority of patients are diagnosed at an advanced stage. Out of all patients with CRC, 35--55% develop hematogenous liver metastasis ([@b7-ol-0-0-10742]). The 5-year survival rate is \~90% for patients with early-stage CRC, but \<10% in patients with distant metastases ([@b8-ol-0-0-10742]). Therefore, it is critical to seek effective anticancer drugs for the treatment of CRC; however, the exact mechanisms of anticancer drugs in CRC are largely unknown.

Ginseng (the root of *Panax ginseng* C.A. Meyer) is a valued traditional medicinal herb found in China and Korea, which is widely used for its health benefits, particularly in these countries ([@b9-ol-0-0-10742]). Ginsenoside Rh1 (Rh1), found in red ginseng, is a metabolite of the major ginsenosides Re and Rg1, formed by intestinal microbiota following the oral ingestion of ginseng ([@b10-ol-0-0-10742],[@b11-ol-0-0-10742]). Rh1 has been reported to possess anti-allergic, anti-inflammatory, anti-aging, antioxidant and antitumor activity ([@b12-ol-0-0-10742]--[@b14-ol-0-0-10742]). Rh1 may also increase learning and memory capacity, as well as hippocampal excitability ([@b15-ol-0-0-10742],[@b16-ol-0-0-10742]). Additionally, other pharmacological effects have been noted, including myocardial injury ([@b17-ol-0-0-10742]) and obesity prevention ([@b18-ol-0-0-10742]), as well as antiplatelet effects ([@b19-ol-0-0-10742]). Additionally, Rh1 induces anticancer effects in several tumor cells, including human hepatocellular carcinoma ([@b20-ol-0-0-10742]), astroglioma ([@b21-ol-0-0-10742]) and acute monocytic leukemia cells ([@b22-ol-0-0-10742]).

Although several studies have investigated the anticancer effects of Rh1, to the best of our knowledge, there have been no reports regarding the effects of Rh1 in CRC to date. The underlying mechanisms of Rh1 on CRC migration and invasion remain unknown. Therefore, in the present study, the regulation of CRC invasion and migration by Rh1 was investigated *in vitro* and *in vivo*.

Materials and methods
=====================

### Cell culture

The human CRC cell line SW620 was purchased from the Type Culture Collection of the Chinese Academy of Sciences. Cells were cultured in RPMI-1640 medium (Gibco; Thermo Fisher Scientific, Inc.) supplemented with 10% heat-inactivated fetal bovine serum (FBS; Gibco; Thermo Fisher Scientific, Inc.), 1% streptomycin and 1% penicillin (all from Invitrogen; Thermo Fisher Scientific, Inc.). The cultured cells were incubated at 37°C with 5% CO~2~.

### Analysis of cell viability and cell proliferation

Ginsenoside Rh1 (purity \>97%) was purchased from Chengdu Must Bio-Technology Co., Ltd. (cat. no. A0240). The effects of Rh1 on SW620 cell viability and proliferation were determined by Cell Counting Kit-8 (CCK-8; Dojindo Molecular Technologies, Inc.) assays. Briefly, SW620 cells in the logarithmic growth phase were seeded into 96-well plates at a density of 2×10^3^ cells/well. Next, for examining cell viability, cells were treated with Rh1 at concentrations of 0, 50 or 100 µM at 37°C for 24 or 48 h, and cells were treated with 0, 50 or 100 µM Rh1 at 37°C for 0, 12, 24 and 48 h to examine cell proliferation. Untreated cell served as the control group. Then, 10 µl CCK-8 reagent was added to each well and cells were incubated at 37°C with 5% CO~2~ for another 2 h. The absorbance of each well was measured at 450 nm using a microplate reader (Thermo Fisher Scientific, Inc.).

### Cell migration assay

Cell migration was determined by a wound healing test. Cells (5×10^5^ cells/well) were seeded into 6-well plates and incubated at 37°C until \>90% confluence was reached. Cell monolayers were carefully scratched using a 10-µl sterile plastic pipette tip to make an artificial wound. The floating cell debris was rinsed twice with PBS. Subsequently, fresh serum-free RPMI-1640 medium containing different concentrations of Rh1 (0 or 100 µM) was added. Images of the wound area were captured at 0 and 24 h under an inverted light microscope (magnification, ×200; Olympus Corporation).

### Matrigel invasion assay

Transwell chambers (pore size, 8-µm; Corning Inc.) were used to examine the cell invasion capacity. The chamber filter was pre-coated with 100 µl diluted Matrigel (BD Biosciences). Cell suspensions (200 µl; 2×10^5^ cells in serum-free RPMI-1640 medium containing 0 or 100 µM Rh1) were added to the upper chamber. The bottom chamber was filled with complete RPMI-1640 medium containing 10% FBS. Following incubation at 37°C with 5% CO~2~ for 24 h, the remaining cells on the top surface of the filter were removed. The invasive cells on the lower surface of the filter were fixed in 4% paraformaldehyde for 10 min and stained in 0.1% crystal violet for 15 min both at room temperature. The invasive cells were imaged and counted using a light microscope (Olympus Corporation) at ×200 magnification in five random fields.

### Reverse transcription-quantitative PCR (RT-qPCR)

SW620 cells (2×10^5^) in the logarithmic growth phase were seeded in 6-well plates until 90% confluence was reached. Subsequently, they were treated with 0 or 100 µM Rh1 at 37°C for 24 h. Total RNA from cells was extracted using TRIzol^®^ reagent (Invitrogen; Thermo Fisher Scientific, Inc.). cDNA synthesis was performed using a PrimeScript™ RT reagent kit with gDNA Eraser (Takara Biotechnology Co., Ltd.). RT reaction conditions were as follows: 37°C for 15 min followed by 85°C for 5 sec. qPCR was performed using SYBR Premix Ex Taq II (Tli RNaseH Plus; Takara Biotechnology Co., Ltd.), according to manufacturer\'s protocol, on an ABI PRISM 7500 Real-Time PCR system (Applied Biosystems; Thermo Fisher Scientific, Inc.). The PCR conditions were as follows: Initial denaturation at 95°C for 30 sec, followed by 40 cycles of denaturation at 95°C for 5 sec and annealing/extension at 60°C for 34 sec. The melting curve was analyzed at the end of amplification. The fold change of each gene was calculated using the 2^−ΔΔCq^ method ([@b23-ol-0-0-10742]) and normalization to GAPDH. The primers were synthesized by GenScript, and the sequences used were: Matrix metallopeptidase (MMP)1 forward, 5′-AGGACTCCAAGGTAGACACAC-3′ and reverse, 5′-TTGCCGTTCTTGTAGGTGAACGC-3′; MMP3 forward, 5′-CCTGCTTTGTCCTTTGATGC-3′, and reverse, 5′-TGAGTCAATCCCTGGAAAGTC-3′; tissue inhibitor of metalloproteinases 3 (TIMP3) forward, 5′-AGTTACCCAGCCCTATGA-3′ and reverse, 5′-GCAAAGGCTTAAACATCT-3′; and GAPDH forward, 5′-GAAGGTGAAGGTCGGAGTC-3′ and reverse, 5′-GAAGATGGTGATGGGATTTC-3′.

### Western blot analysis

SW620 cells (2×10^5^) treated with 0 or 100 µM Rh1 for 24 h as aforementioned were harvested and lysed in RIPA buffer (Beyotime Institute of Biotechnology). Protein concentration was determined by the bicinchoninic acid (BCA) method using a BCA Protein Assay kit (Beijing Solarbio Science & Technology Co., Ltd.) according to the manufacturer\'s protocol. A total of 30 µg of protein was separated via 10% SDS-PAGE. Following electrophoresis, proteins were transferred onto PVDF membranes (Thermo Fisher Scientific, Inc.). Membranes were blocked in TBS with 0.05% Tween 20 (Beijing Solarbio Science & Technology Co., Ltd.) containing 5% skimmed milk at room temperature for 1 h, and subsequently incubated with primary antibodies at 4°C overnight. The primary antibodies (all from Abcam) included: Anti-MMP1 (cat. no. ab38929; 1:5,000), anti-MMP3 (cat. no. ab53015; 1:1,000), anti-ERK1+ERK2 (cat. no. ab17942; 1:1,000), anti-phosphorylated (p-)ERK1 + ERK2 (p-T202 + T204; cat. no. ab214362; 1:1,000), anti-P38 (cat. no. ab197348; 1:1,000), anti-p-P38 (p-T180; cat. no. ab178867; 1:1,000 dilution), anti-JNK1+JNK2 (cat. no. ab112501; 1:1,000), anti-p-JNK1 + JNK2 (p-T183 + T185; cat. no. ab4821; 1:1,000), anti-TIMP3 (cat. no. ab39184; 1:1,000) and anti-GAPDH (cat. no. ab181602; 1:10,000). Next, the membranes were incubated with secondary antibody conjugated to horseradish peroxidase (goat anti-rabbit immunoglobulin G; 1:2,000 dilution; cat. no. ab205718; Abcam) for 1 h at room temperature. The immunopositive bands were visualized using a Pierce ECL Western Blotting kit (Thermo Fisher Scientific, Inc.) according to the manufacturer\'s protocols. Band intensity was determined with the ImageQuant^™^ LAS 4010 biomolecular imager (GE Healthcare Life Sciences) and normalized to GAPDH.

### Nude mouse xenograft model and Rh1 treatment

A total of 6 adult male BALB/c nude mice (4--6 weeks; 20--22 g) were selected for the present study. Nude mice were purchased from Shanghai Experimental Animal Center of the Chinese Academy of Sciences (Shanghai, China). The mice were housed individually in a specific pathogen-free environment with free access to water and food under 26--28°C, 40--60% humidity and 10 h light/14 h dark conditions. The experimental procedures were approved by the Institutional Animal Care and Use Committee of Lanzhou University Second Hospital (Lanzhou, China). Logarithmic growth phase SW620 cells (3×10^6^) were suspended in 250 µl PBS and Matrigel (1:1 ratio; BD Biosciences) and injected subcutaneously into the dorsal right flank of mice. Mice were randomly divided into control and Rh1 groups (3 mice/group). Mice in the control group were orally administered with 2 ml distilled water/day, while mice in Rh1 group were orally administrated with 20 mg/kg/day Rh1, dissolved in 2 ml distilled water, for 35 consecutive days. Tumor volumes were measured once per week. At day 35, mice were sacrificed by decapitation and the tumors were dissected at 12 h after the last drug delivery. The tumor length and width were measured with a caliper, and the volume was calculated using the formula: Volume=0.5 × (length × width)^2^. Images of the tumors in each group were captured and the tumors were weighed.

### Statistical analysis

Statistical analysis was performed using GraphPad Prism version 7 software (GraphPad Software, Inc.). Data are expressed as the means ± SEM of at least three independent experiments. The differences between two groups were analyzed using a Student\'s t-test, and the differences among multiple groups were assessed using one-way ANOVA followed by a Newman Keuls post hoc test. P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### Effects of Rh1 on the viability and proliferation of CRC cells

To investigate the effects of Rh1 on cell viability and proliferation, SW620 cells were treated with various concentrations (0, 50 or 100 µM) of Rh1, and CCK-8 assays were performed. As shown in [Fig. 1A](#f1-ol-0-0-10742){ref-type="fig"}, 50 and 100 µM Rh1 did not influence cell viability in the treatment groups, compared with in the control group. Furthermore, Rh1 treatment for 24 or 48 h did not significantly influence cell viability for the same Rh1 concentrations. These results indicated that Rh1 did not exert significant cytotoxicity on SW620 cells at 0--100 µM for 24 or 48 h. However, 50 and 100 µM Rh1 significantly inhibited cell proliferation (50 µM, P\<0.01; 100 µM, P\<0.001) in the treatment group compared with in the control group ([Fig. 1B](#f1-ol-0-0-10742){ref-type="fig"}). The nontoxic concentration of 100 µM was selected for subsequent experimentation.

### Rh1 inhibits the migration and invasion of CRC cells in vitro

To evaluate the effects of Rh1 on cell migration and invasion, SW620 cells were treated with 0 or 100 µM Rh1 for 24 h. The wound healing assay demonstrated that Rh1 significantly inhibited wound closure. The percentage of the wound area in the Rh1 group was significantly greater than that of the control group (P\<0.01; [Fig. 2A](#f2-ol-0-0-10742){ref-type="fig"}). Similarly, the Transwell invasion assay demonstrated that Rh1 treatment significantly decreased the number of invasive cells, compared with the control group (P\<0.01; [Fig. 2B](#f2-ol-0-0-10742){ref-type="fig"}). These data suggested that Rh1 effectively inhibited the migration and invasion of CRC cells *in vitro*.

### Rh1 suppresses MMP1 and MMP3 expression, increases the expression levels of TIMP3 and inhibits mitogen-activated protein kinase (MAPK) signaling pathway activation

The expression levels of MMP1, MMP3 and TIMP3 were measured in CRC cells via RT-qPCR and western blot analyses, respectively. The results revealed that Rh1 treatment markedly decreased the mRNA expression levels of MMP1 and MMP3, and increased TIMP3 mRNA expression, compared with the control group (P\<0.01; [Fig. 3A-C](#f3-ol-0-0-10742){ref-type="fig"}). Consistently, the protein expression levels of MMP1 and MMP3 were significantly decreased, and TIMP3 expression was increased in the Rh1 group (P\<0.01; [Fig. 3D-G](#f3-ol-0-0-10742){ref-type="fig"}). Additionally, as presented in [Fig. 3H and I](#f3-ol-0-0-10742){ref-type="fig"}, it was demonstrated that Rh1 significantly decreased the ratios of p-P38/P38, p-ERK1/2/ERK1-2 and p-JNK/JNK compared with the control group (P\<0.01). These results suggested that Rh1 inhibited MAPK signaling.

### Inhibitory effects of Rh1 on xenograft tumor growth and MAPK signaling in vivo

To further investigate the antitumor effects of Rh1, a xenograft model of nude mice was established with SW620 cells. Rh1 (0 or 20 mg/kg) was orally administered to treat the tumors in mice, and tumor growth was determined. The tumor volume was significantly decreased in the Rh1 group compared with in the control group after 35 days (P\<0.01; [Fig. 4A](#f4-ol-0-0-10742){ref-type="fig"}). When the tumors were harvested, the tumor weights were measured. Rh1 treatment significantly decreased the tumor weight, compared with the control group (P\<0.01; [Fig. 4B](#f4-ol-0-0-10742){ref-type="fig"}). Additionally, tumor size was markedly decreased in the Rh1 group compared with that in the control group ([Fig. 4C](#f4-ol-0-0-10742){ref-type="fig"}). These results suggested that Rh1 inhibited tumor growth *in vivo*. Additionally, whether Rh1 regulates the MAPK signaling pathway *in vivo* remains unclear. The ratios of p-P38/P38, p-ERK1/2/ERK1-2 and p-JNK/JNK were significantly downregulated in Rh1 treated mice tumor tissues compared with in tissues from the control group (P\<0.01; [Fig. 4D and E](#f4-ol-0-0-10742){ref-type="fig"}).

Discussion
==========

The present study revealed that different concentrations of Rh1 exhibited no toxicity in CRC cells. Rh1 (100 µM) significantly inhibited the proliferation, migration and invasion of CRC cells *in vitro*, and 20 mg/kg Rh1 inhibited tumor growth *in vivo*.

Rh1 is a hydrolysis product that reaches the systemic circulation following ginseng ingestion ([@b24-ol-0-0-10742]), and has been reported to exhibit certain biological activities, including anti-allergic, anti-inflammatory and antitumor activities ([@b12-ol-0-0-10742]--[@b14-ol-0-0-10742]). Previous studies have revealed that Rh1 is involved in cell viability and proliferation. For example, Rh1 inhibits the proliferation of non-alcoholic fatty liver cells ([@b25-ol-0-0-10742]). Conversely, Wang *et al* ([@b26-ol-0-0-10742]) revealed that Rh1 has no effect on human peripheral blood mononuclear cell proliferation up to 100 mg/l. In addition, the cytotoxicity in neuronal cells is not affected by different concentrations of Rh1 ([@b27-ol-0-0-10742]). Rh1 at the concentrations of 0--100 µM was not toxic to CRC cells in the present study. However, cell proliferation was significantly suppressed by Rh1 in a dose-dependent manner. These findings suggested that Rh1 suppressed tumor progression partially due to the inhibition of cell proliferation rather than due to toxic effects. Therefore, a nontoxic concentration was selected for a more accurate assessment of CRC cell migration and invasion.

Migration and invasion are major obstacles in the treatment of cancer, which induce poor prognosis and affect patient survival ([@b28-ol-0-0-10742]). Previous studies have revealed that Rh1 inhibits human cancer migration and invasion: For example, Rh1 exerts inhibitory effects on migration and invasion by suppressing MMP1, MMP3 and MMP9 expression in human astroglioma ([@b21-ol-0-0-10742]). Additionally, Rh1 inhibits THP-1 acute monocytic leukemia cell migration and invasion ([@b22-ol-0-0-10742]). Similarly, the results of the present study demonstrated that Rh1 inhibited CRC cell migration and invasion. However, the molecular mechanisms underlying the inhibition of migration and invasion remain unclear.

MMPs, including MMP1 and MMP3, serve an important role in tumor progression, and are involved in tumor metastasis processes, including angiogenesis, migration and invasion ([@b29-ol-0-0-10742]). High expression levels of MMP1 are associated with lymph node metastasis, and promote tumor growth and metastasis in esophageal squamous cell carcinoma ([@b30-ol-0-0-10742]). In CRC, MMP1 is a prognostic indicator for hematogenous metastasis ([@b31-ol-0-0-10742]). MMP3 is a tumor promoter involved in tumorigenesis and metastasis, which promotes tumor cell migration and invasion ([@b32-ol-0-0-10742]). TIMPs inhibit activated MMPs, keeping the balance of TIMPs and MMPs ([@b33-ol-0-0-10742]). TIMP3 has been reported to be associated with anticancer capability, and regulates cell migration and invasion in osteosarcoma ([@b34-ol-0-0-10742]), cervical cancer ([@b35-ol-0-0-10742]) and esophageal squamous cell carcinoma ([@b36-ol-0-0-10742]). In CRC, TIMP3 is downregulated in tumor tissues and inhibits cell migration and invasion ([@b37-ol-0-0-10742]). The present study measured the expression levels of MMP1 and MMP3, which were decreased following Rh1 treatment. Additionally, Rh1 treatment led to an increase in the expression levels of TIMP3. Thus, it was inferred that Rh1 suppressed CRC cell migration and invasion, at least partially, via suppressing MMP1 and MMP3 expression and promoting TIMP3 expression.

The MAPK signaling pathway consists of four independent cascades. The terminal kinases of these cascades include ERK, Big MAPK-1, JNK and P38 ([@b38-ol-0-0-10742]). The MAPK signaling pathways link extracellular signals to the machinery that controls basic cellular processes, including proliferation, differentiation, invasion, migration and apoptosis ([@b39-ol-0-0-10742],[@b40-ol-0-0-10742]). A previous study revealed that Rh1 suppresses MMP1 expression via inhibition of MAPK signaling ([@b20-ol-0-0-10742]). In addition, Rh1 inhibited the migration and invasion of acute monocytic leukemia cells by inactivating the MAPK signaling pathway ([@b22-ol-0-0-10742]). The present study revealed that Rh1 inhibited the phosphorylation of ERK1/2, p38 and JNK in SW620 cells and tumor-bearing mice tissues, which suggested that Rh1 inhibited the activation of the MAPK signaling pathway not only *in vitro* but also *in vivo*. From this, it was concluded that Rh1 may have suppressed CRC cell migration and invasion via MAPK signaling pathway inactivation.

Furthermore, a xenograft model was established to investigate the effects of Rh1 on tumor growth in mice. It was identified that Rh1 reduced tumor volume and weight, indicating that Rh1 inhibited tumor growth *in vivo*. To the best of our knowledge, this was the first study demonstrating that Rh1 exerted anticancer activity in CRC *in vivo*.

In conclusion, the present study demonstrated that Rh1 significantly reduced CRC cell proliferation, migration and invasion. Rh1 exerted anticancer activity, potentially through inhibiting MMP1 and MMP3 expression, increasing TIMP3 expression, and MAPK signaling pathway inactivation. Furthermore, Rh1 inhibited tumor growth and the MAPK signaling pathway *in vivo*. These findings indicated that Rh1 has potential for development into a novel drug for adjuvant therapy of CRC.

Not applicable.

Funding
=======

No funding was received.

Availability of data and materials
==================================

All data generated or analyzed during this study are included in this published article.

Authors\' contributions
=======================

XL and YCZ designed the study. XL, XX, AS, JG and YWZ performed the experiments and analyzed data. XL mainly wrote the manuscript and YCZ revised it. All authors have read and approved the final manuscript.

Ethics approval and consent to participate
==========================================

The experimental procedures were approved by the Institutional Animal Care and Use Committee of Lanzhou University Second Hospital (Lanzhou, China).

Patient consent for publication
===============================

Not applicable.

Competing interests
===================

The authors declare that they have no competing interests.

![Rh1 has no toxic effect but inhibits proliferation in colorectal cancer cells. (A) SW620 cells were treated with 0, 50 or 100 µM Rh1 for 24 or 48 h, and cell viability was subsequently measured using a CCK-8 assay. (B) Rh1 (0, 50 or 100 µM) was used to treat SW620 cells for 0, 12, 24 and 48 h, and a CCK-8 assay was performed to detect cell proliferation. Data are presented as the means ± SEM. \*\*P\<0.01 and \*\*\*P\<0.001 vs. control group. CCK-8, Cell Counting kit-8; OD, optical density; Rh1, ginsenoside Rh1.](ol-18-04-4160-g00){#f1-ol-0-0-10742}

![Rh1 reduces the migration and invasion capabilities of colorectal cancer cells. (A) Following treatment of SW620 cells with 0 or 100 µM Rh1 for 24 h, cell migration was assessed using a wound healing assay. The percentage of wound width was calculated at 24 h compared with 0 h. (B) SW620 cells were treated with 0 or 100 µM Rh1, and cell invasion was assessed using a Transwell assay. The invasive cells were imaged and counted. Data are presented as the means ± SEM. \*\*P\<0.01 vs. control group. Rh1, ginsenoside Rh1.](ol-18-04-4160-g01){#f2-ol-0-0-10742}

![Rh1 decreases the mRNA and protein expression levels of MMP1 and MMP3, enhances TIMP3 expression and inhibits the phosphorylation of ERK1/2, P38 and JNK. mRNA expression levels of (A) MMP1, (B) MMP3 and (C) TIMP3 were detected using reverse transcription-quantitative PCR following exposure of SW620 cells to 0 or 100 µM Rh1 for 24 h. (D) Protein expression levels of MMP1 and MMP3 were measured using western blotting. GAPDH was used as an internal control. (E) Fold change of MMP1 and MMP3 protein levels was normalized using GAPDH. (F) Protein expression levels of TIMP3 were detected by western blot analysis. GAPDH was used for normalization. (G) Semi-quantified TIMP3 protein expression. (H) Protein expression levels of P38, p-P38, ERK1/2, p-ERK1/2, JNK and p-JNK were assessed using western blotting. GAPDH was used as an internal control. (I) Relative protein expression levels of p-P38, p-ERK1/2 and p-JNK were compared with their total amount. Data are presented as the means ± SEM. \*\*P\<0.01 vs. control group. MMP, matrix metallopeptidase; p-, phosphorylated-; Rh1, ginsenoside Rh1; TIMP3, tissue inhibitor of metalloproteinases 3.](ol-18-04-4160-g02){#f3-ol-0-0-10742}

![Rh1 inhibits tumor growth and the mitogen-activated protein kinase signaling pathway *in vivo*. (A) Tumor volumes were determined every week following Rh1 treatment. (B) Tumor weights were measured when the tumors were dissected. (C) Tumors in control and Rh1 groups were photographed following resection. (D) Protein expression levels of p-P38, P38, p-ERK1/2, ERK1/2, p-JNK and JNK were determined by western blotting. GAPDH was used for normalization. (E) Analysis of western blotting. Data are presented as the means ± SEM. \*\*P\<0.01 vs. control group. p-, phosphorylated-; Rh1, ginsenoside Rh1.](ol-18-04-4160-g03){#f4-ol-0-0-10742}
